In addition, blocking properdin, which inhibits early AP activity, prevented C3 fragment deposition on PNH RBCs from PNH patients with or without eculizumab treatment, while eculizumab did not, as expected (Figure 3E). This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.